← Back to blog

IND Writing Automation: What to Automate and What to Keep Human

November 9, 2026
IND Writing Automation: What to Automate and What to Keep Human

IND writing automation means using AI and workflow tooling to turn source documents into first drafts of IND sections, run consistency checks, and feed the result into eCTD assembly. Done well, it moves your team's time from typing and formatting to scientific review. Done badly, it produces unsupported statements that you, as sponsor, still have to answer for. This guide shows where automation fits in a US IND, what FDA's current materials say about it, and how to set it up so it holds up under scrutiny.

Haiphai
haiphai.com
Make IND Drafting More Efficient
HaiPhai works from your strategic goals to identify bottlenecks and tailor AI-enabled regulatory drafting to your team's needs.
Explore HaiPhai's approach

TL;DR

  • Automate the assembly work: first drafts from source documents, cross-document consistency checks, formatting, and publishing preparation. Keep scientific judgment, strategy and sign-off with qualified people.
  • An IND goes into effect 30 calendar days after FDA receives it unless FDA places a clinical hold or says earlier that the study may begin, so draft quality at submission matters more than speed alone.
  • FDA's January 2025 draft guidance on AI in regulatory decision-making excludes drafting a regulatory submission, where it does not affect patient safety, drug quality or study reliability. Sponsors remain responsible for what they submit.
  • A defensible setup has a documented risk assessment, a written policy on what the AI may do, subject matter expert review, and a clear separation from your GxP systems of record.

Table of Contents

What IND writing automation covers

An IND is a large, structured package. Reporting in The Scientist notes that IND applications run to hundreds or thousands of pages, pulling together animal or foreign human data, clinical trial plans and manufacturing details. They are also living documents: sponsors update them whenever the trial design or manufacturing protocol changes.

The required content is fixed by regulation. Under 21 CFR 312.23(a), an IND includes, in order, the cover sheet (Form FDA-1571), a table of contents, the introductory statement and general investigational plan, the Investigator's Brochure, protocols, chemistry, manufacturing and controls (CMC) information, and pharmacology and toxicology information. FDA's guidance on IND content and format for Phase 1 studies adds that a Phase 1 IND should usually be small, no larger than two to three 3-ring binders, with CMC data appropriate to that phase.

Because the structure is predictable, much of the drafting work is repeatable. Automation can reasonably cover:

  • Source ingestion. Pulling facts, tables and references out of study reports, assay summaries and manufacturing records.
  • First drafts. Generating a starting version of the introductory statement, summaries, background sections and cover letters from those sources.
  • Consistency checks. Comparing numbers, dose levels, product names and dates across the protocol, Investigator's Brochure and nonclinical summaries.
  • Template and section control. Making sure each required section exists, in order, with the right headings.
  • Publishing preparation. Handing a clean, reviewed package to your eCTD publisher.

What it should not do is decide what the data mean. That distinction runs through the rest of this guide.

Where the time goes, and what automation can save

The Scientist reports that an IND can take up to six months to complete, and that quick-drafting with an AI tool may cut that by at least half. In one example it describes, a user generated 50 pages of content in an hour and then spent two months refining the application. The lesson is in that second half: the draft is fast, the refinement is where quality is made.

Most of the delay in a real IND is not typing. It comes from:

  1. Waiting for inputs. Toxicology reports, CMC summaries and clinical protocols arrive on different schedules.
  2. Version drift. A protocol amendment changes a dose, and three downstream documents still carry the old one.
  3. Review loops. Drafts circulate by email, comments conflict, and nobody is sure which version is current.
  4. Late formatting. Publishing issues surface only days before submission.

A good automation design targets all four, not just the drafting step. That is why we start from the milestone you need to hit (a first-in-human date, a financing event, a board commitment) and work backward to the steps that actually gate it. If your bottleneck is a late CMC summary, a faster drafting tool will not move your date.

A practical workflow from source documents to submission

Here is how a biotech team can structure it. Each stage has a clear owner and a clear output.

1. Organize and tag the source material

Collect the study reports, analytical data, manufacturing batch records and prior correspondence. Tag each by type, version and approval status. Automation is only as reliable as what it reads, so retire superseded files before the first draft runs.

2. Generate section drafts with traceable sourcing

Each drafted statement should point back to the document and page it came from. This is the single most useful design choice you can make. A reviewer can then verify a claim in seconds instead of hunting for it, and an unsupported sentence stands out immediately.

3. Run automated quality checks

Before a human reads a word, check for numeric mismatches across documents, missing required sections against the 312.23 order, undefined abbreviations and references that point nowhere. These checks are cheap and catch the errors that cost the most credibility.

Four automated checks for IND drafts

4. Route to subject matter experts

Clinical, nonclinical, CMC and regulatory reviewers each take their own sections. Their edits, comments and approvals are recorded in one place. Our guide to regulatory writing AI use cases lays out which writing tasks suit this treatment first.

5. Assemble and publish

Commercial INDs have been required to use eCTD format since May 2018, while noncommercial and investigator-sponsored INDs are exempt from that mandate but encouraged to submit electronically. Submissions go through the FDA Electronic Submissions Gateway. If publishing is where your team stalls, the 90-day eCTD publishing readiness plan covers how to organize teams and vendors.

6. Track the 30-day clock and what follows

Under 21 CFR 312.40(b), an IND goes into effect 30 calendar days after FDA receives it, unless FDA issues a clinical hold or notifies you earlier that the investigations may begin. Plan your amendments, information requests and site activation steps against that window so the team is not starting them after the clock runs out.

What FDA says about AI in submission drafting

The regulatory picture is more favorable to drafting support than many teams assume, but it carries conditions.

FDA's January 2025 draft guidance on AI to support regulatory decision-making explicitly excludes AI used for operational efficiencies, such as internal workflows, resource allocation, and drafting or writing a regulatory submission, where it does not affect patient safety, drug quality or the reliability of results from a nonclinical or clinical study. The same document stresses early engagement with the Agency to set expectations when a model's use does fall within scope.

The broader framework is a risk-based one. FDA's CDER page on AI in drug development describes a credibility assessment approach tied to the model's context of use, and notes that CDER had seen more than 500 submissions with AI components between 2016 and 2023. In January 2026, FDA also published Guiding Principles of Good AI Practice in Drug Development. Its ten principles include human-centric design, a risk-based approach, adherence to standards including GxP, clear context of use, data governance and documentation, and life cycle management.

Holland & Knight attorneys make a useful distinction: when AI supports initial drafting, such as background sections, executive summaries, cover letters and completeness checks, and qualified people critically review and take ownership of the final content, the risk profile is materially different, and these uses often fall within the operational-efficiency exclusion. Using AI to analyze clinical data that supports a decision is a different matter and calls for more rigor.

This is guidance and commentary, not a ruling on your program. Confirm how it applies to your specific use with your regulatory counsel and, where appropriate, FDA.

What must stay with qualified humans

The sponsor signs the submission. That does not change with automation. The Council on Pharmacy Standards puts the control objective plainly: the sponsor remains responsible for the accuracy, completeness, traceability and integrity of what it submits, and an unsupported AI-generated statement can make a submission unreliable.

In practice, keep these with named experts:

TaskAutomation roleHuman role
Introductory statement and backgroundDraft from approved sourcesConfirm framing and emphasis
Investigational plan and protocol rationalePull in design detailsOwn the scientific rationale
Pharmacology and toxicology summariesSummarize reports, flag inconsistenciesInterpret findings, judge safety margins
CMC sectionsAssemble from batch and analytical recordsConfirm phase-appropriate content and specifications
Cross-document consistencyCheck numbers, names, datesResolve conflicts
Final package and signatureFormat and validateApprove and sign

As Maria de Assis of Axcynsis Therapeutics told The Scientist, AI drafting tools will save time on the bases but not remove the need for in-depth team review. Teams that treat the draft as a first pass and budget real review time get the benefit. Teams that treat it as finished text take on the risk. Our piece on where AI can help in regulatory affairs and what must stay human goes deeper on that boundary.

Compliance controls that make automation defensible

Define the context of use in writing

Write down what the tool is allowed to do (draft background text, check consistency) and what it is not (interpret toxicology, select doses, replace review). Holland & Knight's suggested approach for lower-risk drafting support includes a documented risk assessment aligned with FDA's credibility framework, clear internal policies, human-in-the-loop review by subject matter experts, and clear separation so the AI tool is not treated as a GxP system of record.

Understand where Part 11 applies

Commentary from the Council on Pharmacy Standards notes that FDA reads 21 CFR Part 11 narrowly: it covers certain electronic records required by predicate rules or submitted to FDA, plus applicable electronic signatures. An internal prompt log is not automatically a Part 11 record just because it exists. Many organizations still choose to retain prompt, model, source corpus, reviewer and approval metadata as quality-system controls, which is a sensible habit. If you are mapping which records fall under which rules, our guide to FDA audit trail requirements walks through predicate rules and tamper-evident logging.

Validate what you rely on

The more a tool's output feeds regulated records, the more validation it needs. A seven-step lifecycle approach is laid out in our GxP validation guide for AI, written for QA and regulatory teams together.

Govern access and data

Unpublished data, manufacturing details and strategy documents are among your most sensitive assets. Decide which environments the tool runs in, who can see which source folders, and how outputs are stored. Governance is a design question from day one, and our overview of AI governance platforms for biotech teams explains what to look for.

How to introduce it without disrupting a live program

Pick one bounded use first. A good candidate is the cross-document consistency check on a program already in progress, or the first draft of a lower-risk section such as the introductory statement. Run it in parallel with your current process, compare results, and record what the reviewers corrected.

Then widen scope in steps:

  1. Weeks 1 to 2: map the current IND workflow, owners, handoffs and the dates that matter.
  2. Weeks 3 to 6: pilot drafting and checks on one section family with named reviewers.
  3. Weeks 7 to 10: add routing, version control and sourcing traceability.
  4. Weeks 11 to 13: write the policy, finalize the risk assessment, and train the wider team.

That shape follows the approach in our 90-day pilot for regulatory affairs workflow design. The timings are a template; adjust them to your submission calendar.

The common failure is buying a tool and leaving the process unchanged. The drafts get faster, but approvals still queue behind one overloaded reviewer and the date does not move. Redesign the workflow and the tool together.

Our perspective

We see the same pattern across biotech teams. The IND is rarely late because writing is slow. It is late because inputs arrive out of order, ownership is blurry, and nobody has a live view of what is blocking the next step.

That is why we do not start with software. We start with your strategic goal, such as a first-in-human date or a financing milestone, and trace backward to the bottlenecks that gate it. Then we redesign the workflow around your scientific and regulatory needs, and put AI where it removes real friction: drafting from source documents, checking consistency, and keeping institutional knowledge from living in one person's inbox.

We embed senior experts inside your team so the work happens in live operations, with governance and adoption built in rather than bolted on. Every AI-assisted output has a named human owner and a traceable source. We believe that is what lets a small regulatory team move faster without giving up control of what it signs.

Our aim is to help clients reclaim operational time on the path to approval, because months saved early compound into valuation and funding options later.

John

Work with an embedded operating partner

If your IND timeline is the constraint on your next milestone, we can help you find out why and fix it. Our work begins with a diagnostic of where time is actually lost across clinical, scientific and regulatory operations, followed by tailored workflow redesign, governed automation and expert-led adoption.

Haiphai

See how an embedded engagement works on our partnership page, or read the decision framework for a fractional AI partner versus an internal team if you are weighing how to staff this.

FAQ

Can AI write an entire IND?

It can produce usable first drafts of many sections quickly, but it should not produce the final submission on its own. Qualified experts need to review, edit and take ownership of the content before it enters any regulated system. The sponsor is accountable for accuracy and completeness either way.

Does FDA allow AI to be used in preparing an IND?

FDA's January 2025 draft guidance excludes drafting a regulatory submission from its scope when the AI use does not affect patient safety, drug quality or the reliability of study results. That is a draft document, and your specific use should be assessed by your regulatory and legal advisers. FDA also encourages early engagement where a model's role is more significant.

Which parts of an IND are best suited to automation?

Structured, source-driven content fits best: the cover letter, introductory summaries, background sections, consistency checks across documents, and assembly into the required order. Interpretation of toxicology findings, dose rationale and CMC strategy should stay with your scientists and regulatory leads, with automation supporting the preparation.

How long does an IND take, and how much can automation shorten it?

Reporting in The Scientist puts a typical IND at up to six months, with AI quick-drafting potentially cutting that by at least half in some cases. Your result depends on how much of your delay comes from writing versus waiting for inputs and review cycles, which is why a diagnostic comes first.

Do we need to validate an AI drafting tool?

It depends on how it is used. If the tool is limited to drafting support, with expert review and no role as a system of record, the validation burden is lower than for a tool feeding regulated data. Document the risk assessment and context of use, and align with your quality unit on the right level.

Sources